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This data article contains the data related to the research arti-
cle “Characterization, biorecognitive activity and stability of WGA
grafted lipid nanostructures for the controlled delivery of rifam-
picin” (Pooja et al. 2015) [1]. In the present study, SLN were pre-
pared by a single emulsiﬁcation-solvent evaporation method and
the various steps of SLN preparation are shown in a ﬂow chart. The
preparation of SLN was optimized for various formulation variables
including type and quantity of lipid, surfactant, amount of co-
surfactant and volume of organic phase. Similarly, effect of vari-
ables related to homogezation, sonication and stirring processes,
on the size and surface potential of SLN was determined and
optimized.
& 2015 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Chemistry, lipids and biology
ore speciﬁc sub-
ject areaTargeted nanomedicinevier Inc. This is an open access article under the CC BY license
/j.chemphyslip.2015.09.008
ofﬁce).
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ow data was
acquiredParticle size, polydispersity index and surface charge (Zetasizer, NanoZS,
Malvern)ata format Raw and analyzed
xperimental
factorsFormulation and process parameters were changed for optimization of size
and zeta potential of nanoparticles.xperimental
featuresVarious formulations were prepared by single emulsiﬁcation- solvent eva-
poration method to get nanoparticles of desired size and zeta potential.ata source location NA
ata accessibility The data are presented in this articleD
Value of data
 The article describes the preparation, optimization and characterization of solid lipid nanoparticles.
 The data can be useful for other researchers investigating the effects of different lipids and sur-
factants on size and surface charge of nanoparticles.
 The optimized formulation parameters could be used for the development of solid lipid nano-
particles of hydrophobic drugs.1. Experimental design, material and methods
Solid lipid nanoparticles (SLN) i.e. lipid nanoparticles with solid matrix is the most fascinating
carrier for oral drug delivery because of their excellent biocompatibility, high drug loading, long-term
stability and feasibility for large scale production [1–5]. In this study, solid lipid nanoparticles (SLN)
were prepared by a single emulsiﬁcation-solvent evaporation method. Fig. 1 presents the various
steps of preparation of SLN. Various formulation parameters (Table 1) and process variables (Table 2)
were optimized on the basis of their effect on particle size, polydispersity index and zeta potential.. 1. Flow chart representing the preparation of solid lipid nanoparticles.
Table 1
Optimization of various formulation parameters for the preparation of solid lipid nanoparticles.
Formulation Variable PD (nm) PDI ZP (mV)
Type of lipid
F1 GMS 100 55.5372.4 0.2370.04 23.272.1
F2 Tristearin 100 157.576.7 0.3570.11 26.972.3
F3 Tripalmitin 100 119.573.9 0.4370.08 22.171.9
Quantity of lipid (mg)
F4 GMS 80 49.2873.1 0.2770.09 21.871.6
F1 GMS 100 55.5372.4 0.2370.04 23.272.1
F6 GMS 120 55.0973.7 0.3070.02 29.772.3
Type and concentration of surfactant (%w/v)
F7 Tween 80 1 66.6772.5 0.3670.12 31.872.4
F1 Tween 80 1.5 55.5372.4 0.2370.04 23.272.1
F8 Tween 80 2 133.275.6 0.2770.08 26.671.8
F9 Poloxomer 188 1 61.474.4 0.3870.09 29.972.3
F10 Poloxomer 188 1.5 65.773.9 0.4070.12 26.472.1
F11 Poloxomer 188 2 64.972.8 0.3970.10 23.572.5
F12 PVA 1 120.9276.1 0.1570.09 32.071.9
F13 PVA 1.5 108.8474.3 0.2070.07 26.672.4
F14 PVA 2 102.8674.8 0.2170.11 24.571.8
Volume of organic solvent (mL)
F15 CHCl3 1 48.9172.4 0.3670.11 19.671.4
F16 CHCl3 2 52.8171.9 0.2170.07 24.372.6
F1 CHCl3 3 55.5372.4 0.2370.04 23.272.1
F17 CHCl3 5 47.7372.6 0.2570.04 23.772.3
Quantity of co-surfactant (mg)
F16 lecithin soy 20 52.8171.9 0.2170.07 24.372.6
F18 lecithin soy 30 47.5472.3 0.2170.09 25.571.8
F19 lecithin soy 40 50.3273.1 0.2870.10 28.672.4
GMS: Glyceryl monostearte; PVA: Polyvinyl alcohol; PD: Particle diameter, PDI: Polydispersity index; ZP: Zeta potential.
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volume of organic phase, homogenization speed and time, sonication time, stirring speed and time.
Formulations were prepared by changing one parameter at a time while keeping other parameters
constant.
1.1. Optimization of formulation variables
1.1.1. Type and quantity of lipids
Three different lipids viz. glyceryl monostearte (GMS), tristearin and tripalmitin were used as lipid
matrix. The particle diameter (PD), polydispersity index (PDI) and zeta potential (ZP) were measured
using a Zetasizer NanoZS (Malvern, UK). The lipid showing minimum PD and PDI was selected and
used in three different quantities (80, 100 and 120 mg).
1.1.2. Type and concentration of surfactants
The type and concentration of surfactant affect the particle size as well as stability of nano-
particles. At low concentration, surfactant will not be sufﬁcient to cover the surface of nanoparticles
resulting into increased particle size due to particle aggregation. High concentration of surfactant may
lead to bridging between nanoparticles and may also cause toxicity. Therefore, three different sur-
factants (Tweens80, Poloxomer 188 and polyvinyl alcohol) were evaluated at three different con-
centrations (1%, 1.5% and 2% w/v).
1.1.3. Volume of organic phase
The organic solvent is used to dissolve the lipids and chloroform was used in this study in varying
volumes (1–5 mL). The formulation showing good particle size with minimum volume of solvent was
selected.
Table 2
Optimization of various process variables for preparation solid lipid nanoparticles.
Formulation Variable PD (nm) PDI ZP (mV)
Homogenization speed (rpm)
F20 5000 64.6774.8 0.5670.03 27.572.5
F18 8000 47.5472.3 0.2170.09 25.571.8
21 11000 44.4373.1 0.2670.03 26.572.1
Homogenization time (min)
F22 3 157.9275.7 0.4570.05 30.373.1
F23 4 76.2173.9 0.2870.07 25.872.8
F21 5 44.4373.1 0.2670.03 26.572.1
F24 6 71.2374.8 0.2970.11 23.972.7
Sonication time (min)
F25 5 4500 – –
F26 10 135.4576.7 0.3270.13 27.172.9
F21 15 44.4373.1 0.2670.03 26.572.1
F27 20 49.8972.8 0.2470.09 25.872.6
Stirring speed (rpm)
F28 800 59.0273.9 0.2570.05 20.171.9
F21 1000 44.4373.1 0.2670.03 26.572.1
F29 1200 67.8274.2 0.2770.02 22.972.5
Stirring time (h)
F30 1 69.4874.5 0.4270.07 28.472.7
F31 2 57.3775.1 0.3170.05 26.471.8
F21 3 44.4373.1 0.2670.03 26.572.1
F32 4 61.3473.8 0.2570.09 26.272.5
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Lecithin soy was used as co-surfactant which act as internal emulsiﬁer and favors to particle size
reduction and stability. Lecithin soy was used at different concentration (20, 30 and 40) to get a
formulation having small particle size, less PDI with good zeta potential and stability.
1.2. Optimization of process variables
1.2.1. Homogenization speed and time, sonication time and stirring speed and time
The organic phase was poured in aqueous surfactant phase and homogenized at different speed
(5000, 8000 and 11000 rpm) for different time (3, 4, 5 and 6 min) to get course emulsion. Then this
course emulsion was sonicated for different time period to get a nanoemulsion. Finally formulation
was stirred to evaporate the organic solvent and to get the nanoparticles. The formulation was stirred
at different speed (800, 1000, and 1200 rpm) and for different time period (1, 2 and 3 h) for
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